Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | IDE | P14735 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | HLCS | P50747 | 6/20 | 0.57 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14165464 | 1.00 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL9926313 | 1.00 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31224941 | 1.00 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10002269 | 0.91 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1727527 | 0.91 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13888577 | 0.91 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14922108 | 0.90 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14922112 | 0.90 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL3870139 | 0.89 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10088098 | 0.85 | TDP1 (0.59) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185933-B1 | MATRIPTASE PROTEIN AND USES THEREOF | OXFORD BIOTHERAPEUTICS LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2297580-B1 | Antibody against Ephrin Type-A receptor 7 for treatment of bladder cancer | OXFORD BIOTHERAPEUTICS LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| US-8652478-B2 | Method for treating cancer by administering antibody to ephrin type-A receptor 7 | OXFORD BIOTHERAPEUTICS LTD. (GB) | 2014-02-18 | — | — | US | disclosed |
| US-8637636-B2 | Peptide synthesis apparatuses | THE INVENTION SCIENCE FUND I, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-8420091-B2 | Matriptase protein and uses thereof | OXFORD BIOTHERAPEUTICS LTD. (GB) | 2013-04-16 | — | — | US | disclosed |
| US-20120058131-A1 | PTA089 PROTEIN | OXFORD BIOTHERAPEUTICS LTD (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20110229480-A1 | PTA072 PROTEIN | OXFORD BIOTHERAPEUTICS LTD (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110195074-A1 | Ephrin Type-A Receptor 7 Protein | OXFORD BIOTHERAPEUTICS LTD (GB) | 2011-08-11 | — | — | US | disclosed |
| US-7923533-B2 | Methods for arbitrary peptide synthesis | THE INVENTION SCIENCE FUND I, LLC (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2297580-A2 | PROTEIN | Oxford Biotherapeutics Ltd. (GB) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009150513-A2 | PROTEIN | OXFORD BIOTHERAPEUTICS LTD. (GB) | 2009-12-17 | — | — | WO | disclosed |
| EP-2041295-A2 | METHODS FOR ARBITRARY PEPTIDE SYNTHESIS | Searete LLC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20090035756-A1 | Methods for arbitrary peptide synthesis | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2009-02-05 | — | — | US | disclosed |
| US-20090036649-A1 | Methods for arbitrary peptide synthesis | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2009-02-05 | — | — | US | disclosed |
| US-20080194796-A1 | Methods for arbitrary peptide synthesis | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2008-08-14 | — | — | US | disclosed |
| US-20080004427-A1 | Methods for arbitrary peptide synthesis | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2008-01-03 | — | — | US | disclosed |
| WO-2008002668-A2 | METHODS FOR ARBITRARY PEPTIDE SYNTHESIS | SEARETE LLC (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20050069961-A1 | Isotope-coded affinity tag | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-31 | — | — | US | disclosed |
| EP-1448994-A2 | ISOTOPE-CODED AFFINITY TAG | Bayer HealthCare AG (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003040287-A2 | ISOTOPE-CODED AFFINITY TAG | BAYER HEALTHCARE AG (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050069961-A1 | Isotope-coded affinity tag | YIF1A, RPS27A, QPCTL | TDP1 3556/4885MEN1 3663/4885ABL1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.